Of the 58 mental health patient groups, 33% represent patient interests to regulators, most commonly (22% each) through governmental advisory bodies and/or working with other healthcare advocates. 13% seek to influence healthcare policy and legislation.
33% of respondents from Mental health ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Mental health sub-type
58 patient groups across 6 sub-types
interactions
In its newsletter No. 71 of November 2024, BCC [Belgian Brain Council – Conseil Belge du Cerveau] expressed its support for the statement issued by the Alzheimer Europe association in response to the EMA [European Medicines Agency]'s refusal to grant a marketing authorisation for Leqembi (lecanemab) for the treatment of mild cognitive impairment (memory and thinking disorders).
Dans sa newsletter n°71 de novembre 2024, le BBC a exprimé son soutien à la déclaration de l’association Alzheimer Europe en réaction au refus de l’EMA d’accorder une autorisation de mise sur le marché à Leqembi (lecanemab) pour le traitement des troubles cognitifs légers (troubles de la mémoire et de la pensée).
International mental-health patient group, Belgium
interactions
FamiliarMente sits on the following advisory boards and committees: the National Council for Mental Health and the Regional Councils for Mental Health; the INFARMED [Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. – National Authority of Medicines and Health Products] Medicines Availability Management Monitoring Committee; and the Monitoring Committee for the Implementation of the Legal Framework for Involuntary Treatment (Mental Health Act), amon…
National mental-health patient group, Portugal
actions & advocacy
Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. I…
National mental-health patient group, Australia
actions & advocacy
Convening public hearings in the National Assembly and submitting formal recommendations to the Ministry of Health and Welfare [in Korea].
국회 공청회 개최, 보건복지부 의견 제시 등.
Regional mental-health patient group, Korea
The percentages below highlight how the 23 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
12 mentions
5 mentions
3 mentions
3 mentions
1 mention
7 mentions
5 mentions
1 mention
1 mention
2 mentions
2 mentions
1 mention
1 mention
1 mention
1 mention
actions & advocacy
5 mentions
3 mentions
1 mention
1 mention
3 mentions
2 mentions
1 mention
3 mentions
2 mentions
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
